Date: 03 Dec 2011
Lamotrigine XR Conversion to Monotherapy: First Study Using a Historical Control Group
The efficacy and safety of lamotrigine extended-release tablets (LTG XR) as monotherapy for partial seizures were evaluated using the conversion-to-monotherapy design, and historical data as the control. This methodology was recently approved by the United States Food and Drug Administration, and this study is the first historical control design in epilepsy to complete enrollment. Patients ≥13 years old with uncontrolled partial epilepsy receiving monotherapy with valproate or a noninducing antiepileptic drug were converted to once-daily LTG XR (250 mg or 300 mg) as monotherapy and were followed up for 12 additional weeks. Efficacy was measured by the proportion of patients meeting predefined escape criteria for seizure worsening compared with aggregated pseudoplacebo control data from 8 previously conducted conversion-to-monotherapy trials. Nonoverlap of the 95% confidence limit for LTG XR and the 95% prediction interval of the historical control denotes efficacy. Of 226 randomized patients, 174 (93 in 300 mg/day group and 81 in 250 mg/day group) started withdrawal of the background AED and were evaluated for escape. In the historical control analysis population, the lower 95% prediction interval of the historical control (65.3%) was not overlapped by the upper 95% confidence limit of either LTG XR (300 mg/day; 37.2%) or LTG XR (250 mg/day; 43.4%). Adverse events were reported in 53% and 61% of patients receiving LTG XR (300 mg/day and 250 mg/day, respectively). LTG XR (250 mg or 300 mg once daily) is effective for conversion-to-monotherapy treatment of partial seizures in patients ≥13 years old.
Gilliam FG. Limitations of monotherapy trials in epilepsy. Neurology 2003;60(suppl 4):S26-S30.PubMed
Temple R, Ellenberg SS. Placebo-controlled trials and active-control trials in the evaluation of new treatments. Part 1: ethical and scientific issues. Ann Intern Med 2000;133:455–463.PubMed
Pledger GW, Kramer LD. Clinical trials of investigational antiepileptic drugs: monotherapy designs. Epilepsy 1991;32:716–721.CrossRef
Declaration of Helsinki. Tokyo: World Medical Association, 2004, October 9.
Beydoun A, Kutluay E. Conversion to monotherapy: clinical trials in patients with refractory partial seizures. Neurology 2003;60(suppl 4):S13-S25.PubMed
Gilliam F, Vazquez B, Sackellares et al. An active-control trial of lamotrigine monotherapy for partial seizures. Neurology 1998;51:1018–1025.PubMed
Somerville ER. Aggravation of partial seizures by antiepileptic drugs: is there evidence from clinical trials? Neurology 2002;59:79–83.PubMed
Ryvlin P, Cucherat M, Rheims S. Risk of sudden unexpected death in epilepsy in patients given adjunctive antiepileptic treatment for refractory seizures: a meta-analysis of placebo-controlled randomised trials. Lancet Neurol 2011, Sept 19 [Epub ahead of print].
Rheims S, Perucca E, Cucherat M, Ryvlin P. Factors determining response to antiepileptic drugs in randomized controlled trials. A systematic review and meta-analysis. Epilepsia 2011;52:219–233.PubMed
Food and Drug Administration Center for Drug Evaluation and Research. Summary minutes of the Peripheral and Central Nervous System Drugs Advisory Committee meeting. March 10, 2011. Available at: http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/PeripheralandCentralNervousSystemDrugsAdvisoryCommittee/UCM250489.pdf. Accessed May 5, 2011.
- Lamotrigine XR Conversion to Monotherapy: First Study Using a Historical Control Group
Volume 9, Issue 1 , pp 176-184
- Cover Date
- Print ISSN
- Online ISSN
- Additional Links
- Partial epilepsy
- Clinical trial
- Historical controls
- Industry Sectors
- Author Affiliations
- 1. NYU Comprehensive Epilepsy Center, New York, NY, 10016, USA
- 2. University of Washington, Seattle, WA, 98195, USA
- 3. Ohio State University, Columbus, OH, 43210, USA
- 4. GlaxoSmithKline, Research Triangle Park, NC, 27709, USA